| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | On business and financial situation | The Company releases the press release related to the full year 2021 financial results | Download |
| 23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
| 23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
| 16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 11 May 2022 | On business and financial situation | The Company releases the first quarter 2022 financial results presentation | Download |
| 11 May 2022 | Announcement of general shareholders’ meeting | Rovi releases the information related to its 2022 General Shareholders Meeting | Download |
| 11 May 2022 | On Corporate Governance | The Company informs about the appointment of a new member in its Board of Directors | Download |
| 05 Apr 2022 | Liquidity and counterparty agreements | The Company communicates that it has entered into a liquidity agreement with Bestinver S.V., S.A. | Download |
| 29 Mar 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted on 28 March 2022 and end of the share buyback program | Download |